Artemis Ghana Introduces CLIVE and Expands Its Therapeutic Portfolio
Access to reliable, high-quality medicines remains a cornerstone of effective healthcare systems, particularly in fast-growing markets where demand is rising faster than supply. With this in mind, Artemis Sciences Limited has announced the launch of CLIVE, a new line of advanced antibiotic formulations now available in Ghana, alongside the introduction of additional therapies aimed at gastrointestinal care and nutritional support.
These launches reflect a clear strategic direction: expand access to proven, clinically relevant treatments while maintaining international quality standards.
Introducing CLIVE: A Modern Antibiotic for Today’s Challenges
CLIVE combines Amoxicillin with Clavulanate Potassium, a well-established formulation designed to deliver broad-spectrum antibacterial coverage. By inhibiting beta-lactamase–producing bacteria, the combination enhances effectiveness against resistant infections, an increasingly important consideration in everyday clinical practice.
The product is manufactured to international standards, ensuring consistency, safety, and therapeutic reliability for both prescribers and patients.
CLIVE is available in three formulations:
- CLIVE 625 mg Tablet
- CLIVE 457 mg Suspension
- CLIVE 228.5 mg Suspension
This range allows clinicians to tailor treatment across adult and pediatric populations, improving adherence and clinical outcomes.
Reinforcing Artemis’ Commitment to Ghana’s Healthcare System
The launch of CLIVE is not a standalone event, it is part of Artemis Ghana’s broader commitment to supporting healthcare professionals with dependable, accessible medicines. In a market where treatment continuity and quality assurance matter deeply, Artemis continues to focus on products that meet global benchmarks while remaining locally relevant.
Expanding Beyond Antibiotics: GI Care and Nutrition
In parallel with CLIVE, Artemis has introduced additional therapies addressing common but often under-treated patient needs:
- ULSANIL-OS Suspension
A gastrointestinal therapy combining Sucralfate and Oxetacaine, formulated to provide mucosal protection and symptomatic relief for patients suffering from acid-related disorders. - NINJACAL Oral Suspension
A comprehensive nutritional supplement designed to support bone health, growth, and immunity, particularly relevant for pediatric and at-risk populations.
Together, these products broaden Artemis Ghana’s portfolio across anti-infective, gastrointestinal, and nutritional categories–three pillars of everyday primary care.
Looking Ahead
These launches signal a deliberate shift toward portfolio depth and therapeutic relevance, not just volume. By strengthening its offering across antibiotics, GI therapies, and nutritional supplements, Artemis Ghana is positioning itself as a dependable partner to clinicians and pharmacists navigating increasingly complex patient needs.
In practical terms, this means better treatment choices, improved continuity of care, and a healthcare ecosystem that is less reliant on inconsistent imports. For Artemis, it’s another step toward building resilient, locally anchored healthcare solutions, one product at a time.
